Insider Transactions in Q1 2026 at Amylyx Pharmaceuticals, Inc. (AMLX)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 16
2026
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,995
-0.06%
|
$25,935
$13.89 P/Share
|
|
Jan 16
2026
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,847
+0.08%
|
$19,929
$7.57 P/Share
|
|
Jan 16
2026
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,974
-0.06%
|
$25,662
$13.83 P/Share
|
|
Jan 16
2026
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,818
+0.08%
|
$19,726
$7.57 P/Share
|
|
Jan 15
2026
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
136,193
-3.87%
|
$1,770,509
$13.58 P/Share
|
|
Jan 15
2026
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
197,153
+5.31%
|
$1,380,071
$7.57 P/Share
|
|
Jan 15
2026
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
136,193
-3.87%
|
$1,770,509
$13.59 P/Share
|
|
Jan 15
2026
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
197,182
+5.31%
|
$1,380,274
$7.57 P/Share
|
|
Jan 12
2026
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
17,780
-2.14%
|
-
|
|
Jan 06
2026
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,715
-0.23%
|
$84,865
$11.09 P/Share
|
|
Jan 06
2026
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,715
-0.23%
|
$84,865
$11.09 P/Share
|
|
Jan 06
2026
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,326
-1.84%
|
$36,586
$11.11 P/Share
|